The Relativity Between the Expression of Bcl-2,Ki-67, C-myc and Prognosis of Patients with Malignant Lymphoma
10.3969/j.issn.0253-9896.2009.10.006
- VernacularTitle:Bcl-2、Ki-67和C-myc的表达与恶性淋巴瘤常规治疗后复发的关系
- Author:
Yanling MA
;
Huaqing WANG
;
Xianming LIU
;
Huilai ZHANG
;
Lanfang LI
;
Zhengzi QIAN
- Publication Type:Journal Article
- Keywords:
lymphoma drug therapy;
prognosis;
gene expression;
immunohistochemistry
- From:
Tianjin Medical Journal
2009;37(10):832-834,后插1
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To study the relationship between the expressions of Bel -2, Ki -67, C -myc and prognosis in patients given chemotherapy for malignant lymphoma (ML). Methods: The expressions of Bel-2, Ki-67 and C-myc were measured by immunohistochemistry (IHC) in paraffin-embedded samples of 65 ML cases who received chemotherapy. The survival analysis was done by the Kaplan -Meier method and Log -rank test. Results: For patients with non -Hodgkin lymphoma (NHL) who received chemotherapy, the 3-year disease free survival (DFS) was 22.22% in Bcl-2(+) group compared with that of 55.56% in Bcl-2 (-) group. The difference of DFS was significant between the two groups. Meanwhile, for ML patients, the 3-year DFS was 37.50% in Ki-67(+) group, and 61.54% in Ki-67(-) group respectively(P < 0.05). Conclusion: The expressions of Bcl-2 and Ki-67 were closely related with relapse after chemotherapy in patients with ML. They were useful molecular makers for predicting the prognosis in patients with ML after chemotherapy.
